| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-114 |
DRI_Challenge |
denotes |
Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. |
| T2 |
115-264 |
DRI_Background |
denotes |
BACKGROUND: Since early December 2019, the 2019 novel coronavirus disease (COVID-19) has caused pneumonia epidemic in Wuhan, Hubei province of China. |
| T3 |
265-368 |
DRI_Approach |
denotes |
This study aims to investigate the factors affecting the progression of pneumonia in COVID-19 patients. |
| T4 |
369-493 |
DRI_Challenge |
denotes |
Associated results will be used to evaluate the prognosis and to find the optimal treatment regimens for COVID-19 pneumonia. |
| T5 |
494-605 |
DRI_Background |
denotes |
METHODS: Patients tested positive for the COVID-19 based on nucleic acid detection were included in this study. |
| T6 |
606-710 |
DRI_Background |
denotes |
Patients were admitted to 3 tertiary hospitals in Wuhan between December 30, 2019, and January 15, 2020. |
| T7 |
847-970 |
DRI_Approach |
denotes |
Based on clinical typing results, the patients were divided into a progression group or an improvement/stabilization group. |
| T8 |
971-1062 |
DRI_Approach |
denotes |
Continuous variables were analyzed using independent samples t-test or Mann-Whitney U test. |
| T9 |
1063-1143 |
DRI_Approach |
denotes |
Categorical variables were analyzed using Chi-squared test or Fisher exact test. |
| T10 |
1144-1239 |
DRI_Approach |
denotes |
Logistic regression analysis was performed to explore the risk factors for disease progression. |
| T11 |
1240-1363 |
DRI_Background |
denotes |
RESULTS: Seventy-eight patients with COVID-19-induced pneumonia met the inclusion criteria and were included in this study. |
| T12 |
1364-1518 |
DRI_Background |
denotes |
Efficacy evaluation at 2 weeks after hospitalization indicated that 11 patients (14.1%) had deteriorated, and 67 patients (85.9%) had improved/stabilized. |
| T13 |
1519-1698 |
DRI_Background |
denotes |
The patients in the progression group were significantly older than those in the disease improvement/stabilization group (66 [51, 70] vs. 37 [32, 41] years, U = 4.932, P = 0.001). |
| T14 |
1699-1877 |
DRI_Approach |
denotes |
The progression group had a significantly higher proportion of patients with a history of smoking than the improvement/stabilization group (27.3% vs. 3.0%, χ = 9.291, P = 0.018). |
| T15 |
1878-2152 |
DRI_Outcome |
denotes |
For all the 78 patients, fever was the most common initial symptom, and the maximum body temperature at admission was significantly higher in the progression group than in the improvement/stabilization group (38.2 [37.8, 38.6] vs. 37.5 [37.0, 38.4]°C, U = 2.057, P = 0.027). |
| T16 |
2153-2435 |
DRI_Approach |
denotes |
Moreover, the proportion of patients with respiratory failure (54.5% vs. 20.9%, χ = 5.611, P = 0.028) and respiratory rate (34 [18, 48] vs. 24 [16, 60] breaths/min, U = 4.030, P = 0.004) were significantly higher in the progression group than in the improvement/stabilization group. |
| T17 |
2436-2623 |
DRI_Background |
denotes |
C-reactive protein was significantly elevated in the progression group compared to the improvement/stabilization group (38.9 [14.3, 64.8] vs. 10.6 [1.9, 33.1] mg/L, U = 1.315, P = 0.024). |
| T18 |
2624-2783 |
DRI_Approach |
denotes |
Albumin was significantly lower in the progression group than in the improvement/stabilization group (36.62 ± 6.60 vs. 41.27 ± 4.55 g/L, U = 2.843, P = 0.006). |
| T19 |
2784-2944 |
DRI_Approach |
denotes |
Patients in the progression group were more likely to receive high-level respiratory support than in the improvement/stabilization group (χ = 16.01, P = 0.001). |
| T20 |
2945-3457 |
DRI_Approach |
denotes |
Multivariate logistic analysis indicated that age (odds ratio [OR], 8.546; 95% confidence interval [CI]: 1.628-44.864; P = 0.011), history of smoking (OR, 14.285; 95% CI: 1.577-25.000; P = 0.018), maximum body temperature at admission (OR, 8.999; 95% CI: 1.036-78.147, P = 0.046), respiratory failure (OR, 8.772, 95% CI: 1.942-40.000; P = 0.016), albumin (OR, 7.353, 95% CI: 1.098-50.000; P = 0.003), and C-reactive protein (OR, 10.530; 95% CI: 1.224-34.701, P = 0.028) were risk factors for disease progression. |
| T21 |
3458-3677 |
DRI_Challenge |
denotes |
CONCLUSIONS: Several factors that led to the progression of COVID-19 pneumonia were identified, including age, history of smoking, maximum body temperature on admission, respiratory failure, albumin, C-reactive protein. |
| T22 |
3678-3771 |
DRI_Challenge |
denotes |
These results can be used to further enhance the ability of management of COVID-19 pneumonia. |
